• Mallinckrodt ($MNK) announced that it has completed the divestment of its nuclear imaging unit to radiopharmacy outfit IBA Molecular, before tax, including up-front and contingent considerations and the assumption of long-term obligations. The deal is priced at $690 million. It was first announced in August, 2016.
The company’s Nuclear Imaging operations encompass two manufacturing facilities. The company is now looking to transform its portfolio with durable and innovative specialty pharmaceutical assets. Mallinckrodt will pay $574 million in up-front consideration, assume approximately $39 million of long-term obligations, and approximately $77 million of contingent consideration.